The Medical Letter on Drugs and Therapeutics
Bimatoprost 0.03% Solution (Latisse) for Eyelash Enhancement
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the prostaglandin analog bimatoprost in a 0.03% solution (Latisse – Allergan) for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes. The same drug, marketed as Lumigan (Allergan), is indicated for reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension1; it was during clinical trials for this indication that increased eyelash length was frequently observed in patients taking bimatoprost.

BACKGROUND — How prostaglandin analogs cause hair growth is unknown. Prostaglandin receptors can be found in the dermal papilla and outer root sheaths of hair follicles.2 Administered topically or systemically, these drugs have led to hair regrowth in macaque monkeys with androgenetic alopecia and in mice with radiation or doxorubicin-induced ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bimatoprost 0.03% Solution (Latisse) for Eyelash Enhancement
Article code: 1313c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian